ArticleAdvances in experimental medicine and biology2023
Computational Models for Biomarker Discovery.
Article in Advances in experimental medicine and biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a prevalent and debilitating neurodegenerative disorder characterized by progressive cognitive decline. Early diagnosis and accurate prediction of disease progression are critical for developing effective therapeutic interventions. In recent years, computational models have emerged as powerful tools for biomarker discovery and disease prediction in Alzheimer's and other neurodegenerative diseases. This paper explores the use of computational models, particularly machine learning techniques, in analyzing large volumes of data and identifying patterns related to disease progression. The significance of early diagnosis, the challenges in classifying patients at the mild cognitive impairment (MCI) stage, and the potential of computational models to improve diagnostic accuracy are examined. Furthermore, the importance of incorporating diverse biomarkers, including genetic, molecular, and neuroimaging indicators, to enhance the predictive capabilities of these models is highlighted. The paper also presents case studies on the application of computational models in simulating disease progression, analyzing neurodegenerative cascades, and predicting the future development of Alzheimer's. Overall, computational models for biomarker discovery offer promising opportunities to advance our understanding of Alzheimer's disease, facilitate early diagnosis, and guide the development of targeted therapeutic strategies.
Indexed as
Identifiers
37486506What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.